Application Serial No. 10/550,448 (Attorney Docket No. 427-US-PCT) Response to Non-Final Office Action Dated: December 18, 2008 Page 2 of 10

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claim 1 (currently amended): A substituted p-diaminobenzene derivative of the general formula

wherein:

s is 0 or 1:

U is O, S, SO₂, SONR¹¹, CO-O-or CONR¹¹; wherein:

 $R^{11} \text{ is hydrogen, } C_{1:6}\text{-alk(en/yn)yl, } C_{3:8}\text{-cycloalk(en)yl, or } C_{3:8}\text{-cycloalk(en)yl-} C_{1:6}\text{-alk(en/yn)yl; or}$

R² and R¹¹ taken together with the nitrogen atom form a 5-8 membered saturated or unsaturated ring, which optionally contains 1, 2 or 3 further heteroatoms:

q is 0 or 1;

X is CO or SO₂; with the proviso that q is 0 when X is SO₂;

Z is O or S;

 $R^{1} \text{ is hydrogen, } C_{1:6}\text{-alk(en/yn)yl, } C_{3:8}\text{-cycloalk(en)yl, } C_{3:8}\text{-cycloalk(en)yl-}C_{1:6}\text{-alk(en/yn)yl, acyl, hydroxy-}C_{1:6}\text{-alk(en/yn)yl, hydroxy-}C_{3:8}\text{-cycloalk(en)yl, hydroxy-}C_{3:8}\text{-cycloalk(en)yl-}C_{1:6}\text{-alk(en/yn)yl, halo-}C_{1:6}\text{-alk(en/yn)yl, halo-}C_{3:8}\text{-cycloalk(en)yl-}C_{1:6}\text{-alk(en/yn)yl, cyano-}C_{1:6}\text{-alk(en/yn)yl, cyano-}C_{3:8}\text{-cycloalk(en)yl-}C_{1:6}\text{-alk(en/yn)yl, cyano-}C_{1:6}\text{-alk(en/yn)yl, cyano-}C_{3:8}\text{-cycloalk(en)yl-}C_{1:6}\text{-alk(en/yn)yl, cyano-}C_{1:6}\text{-alk(en/yn)yl}$

Application Serial No. 10/550,448 (Attorney Docket No. 427-US-PCT) Response to Non-Final Office Action Dated: December 18, 2008 Page 3 of 10

 $R^2 \text{ is hydrogen, } C_{1.6^-alk(en/yn)yl, } C_{3.8^-cycloalk(en)yl, } C_{3.8^-cycloalk(en)yl-C_{1.6^-}} \\ \text{alk(en/yn)yl, } Ar, Ar-C_{1.6^-alk(en/yn)yl, } Ar-C_{3.8^-cycloalk(en)yl, } Ar-C_{3.8^-cycloalk(en)yl-C_{1.6^-}} \\ \text{alk(en/yn)yl, } \text{acyl, } \text{hydroxy-} C_{1.6^-alk(en/yn)yl, } \text{hydroxy-} C_{3.8^-cycloalk(en)yl, } \text{hydroxy-} C_{3.8^-} \\ \text{cycloalk(en)yl-} C_{1.6^-alk(en/yn)yl, } \text{halo-} C_{1.6^-alk(en/yn)yl, } \text{halo-} C_{3.8^-cycloalk(en)yl-} C_{1.6^-alk(en/yn)yl, } \text{cyano-} C_{3.8^-cycloalk(en)yl-} C_{1.6^-alk(en/yn)yl, } NR^{10}R^{10^-} C_{3.8^-cycloalk(en)yl-} \\ \text{cyano-} C_{3.8^-cycloalk(en)yl-} C_{1.6^-alk(en/yn)yl, } NR^{10}R^{10^-} C_{3.8^-cycloalk(en)yl-} \\ \text{cycloalk(en)yl-} ONR^{10}R^{10^-} C_{3.8^-cycloalk(en)yl-} \\ \text{cycloalk(en)yl-} ONR^{10}R^{10$

 $R^{10} \ and \ R^{10} \ are each independently hydrogen, C_{1-6}\text{-}alk(en/yn)yl, C_{3.8}\text{-}cycloalk(en)yl, C_{3.8}\text{-}cycloalk(en)yl, C_{3.8}\text{-}cycloalk(en)yl, C_{1.6}\text{-}alk(en/yn)yl, hydroxy-C_{1.6}\text{-}alk(en/yn)yl, hydroxy-C_{3.8}\text{-}cycloalk(en)yl, hydroxy-C_{3.8}\text{-}cycloalk(en)yl, hydroxy-C_{3.8}\text{-}cycloalk(en)yl-C_{1.6}\text{-}alk(en/yn)yl, halo-C_{1.6}\text{-}alk(en/yn)yl, halo-C_{3.8}\text{-}cycloalk(en)yl-C_{1.6}\text{-}alk(en/yn)yl, cyano-C_{3.8}\text{-}cycloalk(en)yl-C_{1.6}\text{-}alk(en/yn)yl, or cyano-C_{3.8}\text{-}cycloalk(en)yl-C_{1.6}\text{-}alk(e$

 R^{10} and R^{10} taken together with the nitrogen atom form a 5-8 membered saturated or unsaturated ring, which optionally contains 1, 2 or 3 further heteroatoms, with the proviso that:

when R² is halogen or cyano, then s is 0; and

when s is 1 and R2 is a hydrogen atom or acyl, then U is O or S;

 $R^3 \text{ is } C_{1:6}\text{-}\text{alk}(\text{en/yn})yl, C_{3:8}\text{-}\text{cycloalk}(\text{en})yl, \text{ heterocycloalk}(\text{en})yl, C_{3:8}\text{-}\text{cycloalk}(\text{en})yl-C_{1.6}\text{-}\text{alk}(\text{en/yn})yl, C_{1:6}\text{-}\text{alk}(\text{en/yn})yl-C_{3:8}\text{-}\text{cycloalk}(\text{en})yl, C_{1:6}\text{-}\text{alk}(\text{en/yn})yl-C_{3:8}\text{-}\text{cycloalk}(\text{en})yl, C_{1:6}\text{-}\text{alk}(\text{en/yn})yl, \text{ Ar-C}_{3:8}\text{-}\text{cycloalk}(\text{en})yl, \text{ Ar-heterocycloalk}(\text{en})yl, Ar-C_{3:8}\text{-}\text{cycloalk}(\text{en})yl, \text{ Ar-C}_{3:8}\text{-}\text{cycloalk}(\text{en})yl, Ar-C_{3:8}\text{-}\text{cycloalk}(\text{en})yl, \text{ Ar-C}_{1:6}\text{-}\text{alk}(\text{en/yn})yl-C_{3:8}\text{-}\text{cycloalk}(\text{en})yl, \text{ Ar-C}_{1:6}\text{-}\text{alk}(\text{en/yn})yl-C_{3:8}\text{-}\text{cycloalk}(\text{en})yl, C_{1:6}\text{-}\text{alk}(\text{en/yn})yl, C_{3:8}\text{-}\text{cycloalk}(\text{en})yl, C_{1:6}\text{-}\text{alk}(\text{en/yn})yl, C_{3:8}\text{-}\text{cycloalk}(\text{en})yl, C_{1:6}\text{-}\text{alk}(\text{en/yn})yl, C_{3:8}\text{-}\text{cycloalk}(\text{en})yl, C_{1:6}\text{-}\text{alk}(\text{en/yn})yl, C_{1:6}\text{-}\text{alk}(\text{en/yn})yl, C_{3:8}\text{-}\text{cycloalk}(\text{en})yl, C_{1:6}\text{-}\text{alk}(\text{en/yn})yl, C_{3:8}\text{-}\text{cycloalk}(\text{en})yl, C_{1:6}\text{-}\text{alk}(\text{en/yn})yl, C_{3:8}\text{-}\text{cycloalk}(\text{en})yl, C_{1:6}\text{-}\text{alk}(\text{en/yn})yl, C_{3:8}\text{-}\text{cycloalk}(\text{en})yl, C_{1:6}\text{-}\text{alk}(\text{en/yn})yl, C_{3:8}\text{-}\text{cycloalk}(\text{en})yl, C_{1:6}\text{-}\text{alk}(\text{en/yn})yl, C_{3:8}\text{-}\text{cycloalk}(\text{en})yl, C_{3:8}\text{-}\text{cycloalk}(\text{en})$

Application Serial No. 10/550,148 (Attorney Docket No. 427-US-PCT) Response to Non-Final Office Action Dated: December 18, 2008 Page 4 of 10

$$\begin{split} &C_{1.6}\text{-}alk(en/yn)yl-heterocycloalk(en)yl, halo-C_{1.6}\text{-}alk(en/yn)yl, halo-C_{3.8}\text{-}cycloalk(en)yl, halo-C_{3.8}\text{-}cycloalk(en)yl, halo-C_{3.8}\text{-}cycloalk(en)yl-C_{1.6}\text{-}alk(en/yn)yl, halo-C_{3.8}\text{-}cycloalk(en)yl-C_{3.8}\text{-}cycloalk(en)yl-C_{1.6}\text{-}alk(en/yn)yl-Ar, halo-C_{3.8}\text{-}cycloalk(en)yl-Ar, halo-C_{3.8}\text{-}cycloalk(en)yl-Ar, halo-C_{3.8}\text{-}cycloalk(en)yl-Ar, halo-C_{3.8}\text{-}cycloalk(en)yl-Ar, halo-C_{3.8}\text{-}cycloalk(en)yl-Ar, halo-C_{3.8}\text{-}cycloalk(en)yl-Ar, cyano-C_{3.6}\text{-}cycloalk(en)yl-Ar, cyano-C_{3.6}\text{-}cycloalk(en)yl, cyano-heterocycloalk(en)yl, cyano-C_{3.8}\text{-}cycloalk(en)yl, cyano-C_{3.6}\text{-}alk(en/yn)yl-C_{3.8}\text{-}cycloalk(en)yl, cyano-C_{1.6}\text{-}alk(en/yn)yl-heterocycloalk(en)yl, acyl-C_{1.6}\text{-}alk(en/yn)yl, acyl-C_{3.8}\text{-}cycloalk(en)yl, acyl-C_{1.6}\text{-}alk(en/yn)yl, acyl-C_{1.6}\text{-}alk(en/yn)yl, acyl-C_{1.6}\text{-}alk(en/yn)yl-C_{3.8}\text{-}cycloalk(en)yl, acyl-C_{1.6}\text{-}alk(en/yn)yl, acyl-C_{1.6}\text{-}alk(en/$$

 $R^{12} \ and \ R^{12} \ are each independently hydrogen, \ C_{1.6} \ alk(en/yn)yl, \ C_{3.8} - cycloalk(en)yl-C_{1.6} \ alk(en/yn)yl, \ Ar, \ Ar-C_{1.6} \ alk(en/yn)yl, \ Ar-C_{3.8} - cycloalk(en)yl-C_{1.6} \ alk(en/yn)yl, \ Ar, \ Ar-C_{1.6} \ alk(en/yn)yl, \ Ar-cycloalk(en)yl, \ Ar-cycloalk(en)yl-C_{1.6} \ alk(en/yn)yl, \ alo-C_{3.8} \ cycloalk(en)yl, \ alo-C_{$

R¹² and R¹² taken together with the nitrogen atom form a 5-8 membered saturated or unsaturated ring, which optionally contains 1, 2 or 3 further heteroatoms; with the proviso that when R³ is NR¹²R¹² then q is 0; and

Y is a group of formula XXXXI:

Application Serial No. 10/550,448 (Attorney Docket No. 427-US-PCT) Response to Non-Final Office Action Dated: December 18, 2008 Page 5 of 10

wherein:

" \mid " represents a bond attaching the group represented by Y to the carbon atom; V is C or CH; and

k is 0, 1, 2 or 3; and

each R^3 is independently $C_{1.6}$ -alk(en/yn)yl, $C_{3.8}$ -cycloalk (en)yl, $C_{3.8}$ -cycloalk(en)yl- $C_{1.6}$ -alk(en/yn)yl, Ar, $C_{3.8}$ -cycloalk(en)yl, Ar- $C_{3.8}$ -cycloalk(en)yl- $C_{1.6}$ -alk(en/yn)yl, Ar- $C_{3.8}$ -cycloalk(en)yl, Ar- $C_{3.8}$ -cycloalk(en)yl, $C_{1.6}$ -alk(en/yn)yl-heterocycloalk(en)yl, Ar-oxy- $C_{3.8}$ -cycloalk(en)yl- $C_{1.6}$ -alk(en/yn)yl, acyl, $C_{1.6}$ -alk(en/yn)yloxy, $C_{3.8}$ -cycloalk(en)yl- $C_{1.6}$ -alk(en/yn)yloxy, $C_{3.8}$ -cycloalk(en)yl- $C_{1.6}$ -alk(en/yn)yloxy, $C_{3.8}$ -cycloalk(en)yl- $C_{1.6}$ -alk(en/yn)yloxy, $C_{3.8}$ -cycloalk(en)yl- $C_{1.6}$ -alk(en/yn)yl, halo- $C_{3.8}$ -cycloalk(en)yl- $C_{1.6}$ -alk(en/yn)yl, cyano- $C_{3.8}$ -cycloalk(en)yl- $C_{1.6}$ -alk(en/yn)yl, $C_{1.6}$

two adjacent R⁵ groups taken together with the aromatic group form a 5-8 membered ring, which optionally contains one or two heteroatoms; wherein:

 $R^6 \ and \ R^6 \ are each independently \ hydrogen, \ C_{1.6} - alk(en/yn)yl, \ C_{3.8} - cycloalk(en)yl, \ C_{3.8} - cycloalk(en)yl-C_{1.6} - alk(en/yn)yl \ or \ Ar;$

 R^7 and R^7 are <u>each</u> independently hydrogen, C_{1-6} -alk(en/yn)yl, C_{3-8} -cycloalk(en)yl, C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, Ar, heterocycloalk(en)yl- C_{1-6} -alk(en/yn)yl, heterocycloalk(en)yl- C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, heterocycloalk(en)yl-Ar or acyl; or

 R^7 and R^7 taken together with the nitrogen atom form a 5-8 membered saturated or unsaturated ring which optionally contains 1, 2 or 3 further heteroatoms; and

 $R^8 \text{ is hydrogen, } C_{1\text{-6}\text{-}alk(en/yn)yl, } C_{3\text{-8}\text{-}cycloalk(en)yl, } C_{3\text{-8}\text{-}cycloalk(en)yl, } C_{1\text{-6}\text{-}alk(en/yn)yl, } Ar \text{ or -}NR^9R^9\text{'}, \text{ wherein:}$

 R^9 and R^9 are each independently hydrogen, $C_{1:6}$ -alk(en/yn)yl, $C_{3:8}$ -cycloalk(en)yl or $C_{3:8}$ -cycloalk(en)yl- $C_{1:6}$ -alk(en/yn)yl;

Application Serial No. 10/550,448 (Attorney Docket No. 427-US-PCT) Response to Non-Final Office Action Dated: December 18, 2008 Page 6 of 10

or salts thereof.

Claim 2 (previously presented): The compound according to claim 1, wherein R^1 is C_{1-6} -alk(en/yn)yl or a hydrogen atom.

Claim 3 (previously presented): The compound according to claim 1, wherein s is 0.

Claim 4 (previously presented): The compound according to claim 1, wherein s is 1.

Claim 5 (previously presented): The compound according to claim 4, wherein U is an oxygen atom

Claim 6 (previously presented): The compound according to claim 1, wherein R^2 is hydrogen, $C_{1:6}$ -alk(en/yn)yl, $C_{3:8}$ -cycloalk(en)yl, Ar, Ar- $C_{1:6}$ -alk(en/yn)yl, halogen, halo- $C_{1:6}$ -alk(en/yn)yl or cyano; with the provisos that when R^2 is halogen or cyano, then s is 0; and when s is 1 and R^2 is a hydrogen atom, then U is O or S.

Claim 7 (previously presented): The compound according to claim 1, wherein Z is an oxygen atom

Claim 8 (previously presented): The compound according to claim 1, wherein Z is a sulfur atom.

Claim 9 (previously presented): The compound according to claim 1, wherein q is 0.

Claim 10 (previously presented): The compound according to claim 1, wherein q is 1.

Claim 11 (previously presented): The compound according to claim 1, wherein X is CO.

Claim 12 (previously presented): The compound according to claim 1, wherein R^3 is $C_{1:6}$ -alk(en/yn)yl, $C_{3:8}$ -cycloalk(en)yl, $C_{3:8}$ -cycloalk(en)yl- $C_{1:6}$ -alk(en/yn)yl, heterocycloalk(en)yl, $C_{1:6}$ -alk(en/yn)yl, Ar-oxy- $C_{1:6}$ -alk(en/yn)yl, Ar- $C_{1:6}$ -alk(en/yn)yl, Ar-oxy- $C_{1:6}$ -alk(en/yn)yl, Ar- $C_{1:6}$ -alk(en/yn)yloxy- $C_{1:6}$ -alk(en/yn)yl, $C_{1:6}$ -alk(en/yn)yl, $C_{1:6}$ -alk(en/yn)yl, $C_{1:6}$ -alk(en/yn)yl, $C_{1:6}$ -alk(en/yn)yl, $C_{1:6}$ -alk(en/yn)yl, or optionally substituted $NR^{12}R^{12}$ - $C_{1:6}$ -alk(en/yn)yl, or optionally substituted $NR^{12}R^{12}$ - $C_{1:6}$ -alk(en/yn)yl, or optionally

Claim 13 (previously presented): The compound according to claim 12, wherein R^{12} and R^{12} are each independently hydrogen, C_{16} -alk(en/yn)yl or Ar.

Claims 14-20 (cancelled).

Application Serial No. 10/550,448 (Attorney Docket No. 427-US-PCT) Response to Non-Final Office Action Dated: December 18, 2008 Page 7 of 10

Claim 21 (previously presented): The compound according to claim 1, wherein V is CH. Claims 22-24 (cancelled).

Claim 25 (previously presented): The compound according to claim 1, wherein each R^5 is independently $C_{1:6}$ -alk(en/yn)yl, $C_{1:6}$ -alk(en/yn)yl-heterocycloalk(en)yl, Ar, $C_{1:6}$ -alk(en/yn)yloxy, Ar-oxy, $C_{1:6}$ -alk(en/yn)yloxy-carbonyl, halogen, halo- $C_{1:6}$ -alk(en/yn)yl, NR^7R^7 , S- R^8 or SO_2R^8 , or two adjacent R^5 groups taken together with the aromatic group form a 5-8 membered ring, which optionally contains one or two heteroatoms.

Claim 26 (previously presented): The compound according to claim 25, wherein both R^7 and R^7 are $C_{1:6}$ -alk(en/yn)yl.

Claim 27 (previously presented): The compound according to claim 25, wherein R⁸ is C₁₋₆-alk(en/yn)yl or Ar.

Claim 28 (previously presented) The compound according to claim 1, wherein the compound is:

- 2-(4-Fluorophenyl)-N-{2-methyl-4-[(6-p-tolyloxypyridin-3-ylmethyl)-amino]-phenyl}-acetamide:
- 2-(4-Fluorophenyl)-N-{2-methyl-4-[(6-trifluoromethylpyridin-3-ylmethyl)-amino]-phenyl}-acetamide;
- 3,3-Dimethyl-N-{2-methyl-4-[(6-p-tolyloxypyridin-3-ylmethyl)-amino]-phenyl}-butyramide;
- 3,3-Dimethyl-N-{2-methyl-4-[(6-trifluoromethylpyridin-3-ylmethyl)-amino]-phenyl}-butyramide;
- N-(4-{[6-(4-Cyanophenoxy)-pyridin-3-ylmethyl]-amino}-2-methylphenyl)-2-(4-fluorophenyl)-acetamide;
- N-{4-[(6-Chloropyridin-3-ylmethyl)-amino]-2-methylphenyl}-2-(4-fluorophenyl)-acetamide, or
- 2,2-Dimethyl-N-{2-methyl-4-[(6-phenoxypyridin-3-ylmethyl)-amino]-phenyl}-proprionamide; or a salt thereof

Application Serial No. 10/550,448 (Attorney Docket No. 427-US-PCT) Response to Non-Final Office Action Dated: December 18, 2008 Page 8 of 10

Claim 29 (previously presented) A pharmaceutical composition comprising one or more pharmaceutically acceptable carriers or diluents and a compound according to claim 1.

Claims 30-45 (cancelled).